# **Product** Data Sheet

### **Emidurdar**

Cat. No.:HY-105917CAS No.:265646-85-3Molecular Formula: $C_{16}H_9BrF_6N_6O$ Molecular Weight:495.18

Target: Chloride Channel

Pathway: Membrane Transporter/Ion Channel

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

-20°C 1 year

#### **SOLVENT & SOLUBILITY**

In Vitro DMSO: 125 mg/mL (252.43 mM; Need ultrasonic)

H<sub>2</sub>O: < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.0195 mL	10.0973 mL	20.1947 mL
	5 mM	0.4039 mL	2.0195 mL	4.0389 mL
	10 mM	0.2019 mL	1.0097 mL	2.0195 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.20 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.20 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	Endovion is a pharmacological anion channel inhibitor (like chloride channel) and the specific VRAC/VSOAC blocker. Endovion (NS3728) is also an Anoctamin-1 (ANO 1) channel inhibitor <sup>[1][2]</sup> .
IC <sub>50</sub> & Target	Chloride channel, $VRAC/VSOAC^{[1]}$ . $ANO1^{[2]}$ .
In Vitro	Endovion (NS3728, 10-100 $\mu$ M) reduces TNF $\alpha$ -induced apoptosis and increases p53-protein level as well as downstream signaling, e.g., expression of p21 <sup>Waf1/Cip1</sup> , Bax, Noxa, MDM2, and activation of Caspase-9/-3 in Cisplatin-sensitive cells <sup>[1]</sup> . ?Endovion (NS3728, 10 $\mu$ M) inhibits cell proliferation in Capan-1, AsPC-1 and BxPC-3 cell lines <sup>[2]</sup> .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis<sup>[1]</sup>

Cell Line: Wild-type, resistant, and transiently transfected A2780 cells.

Concentration: 10-100 μM.

Incubation Time: 18 or 4.5 h.

Result: Reduced the maximal taurine rate constant more than 90% compared with the untreated control cells.

Significantly reduceed p53 and p21Waf1/Cip1 protein level in A2780WT cells.

Resulted in an increased LRRC8A protein expression.

Cell Proliferation Assay<sup>[2]</sup>

Cell Line:	Capan-1, AsPC-1, BxPC-3 and H6c7 cell lines.	
Concentration:	10 μΜ.	
Incubation Time:	24 h.	
Result:	Resulted in the most pronounced inhibition in all cell lines with 77 $\pm$ 26 $\%$ in Capan-1, 67 $\pm$ 9 $\%$ in AsPC-1, and 54 $\pm$ 8 $\%$ in BxPC-3 cells at +67 mV.	

### **CUSTOMER VALIDATION**

• Nat Commun. 2021 Jul 22;12(1):4457.

See more customer validations on www.MedChemExpress.com

#### **REFERENCES**

[1]. Sørensen BH, et al. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against CDDP-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation. Am J Physiol Cell Physiol. 2016 Jun 1;310(11):C857-73.

[2]. Sauter DR, et al. ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC). Pflugers Arch. 2015 Jul;467(7):1495-1508.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA